60.02USD-1.57%Mkt Cap: 5.36B USDP/E: 354.26Last update: 2026-05-26
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPI…
Industry Peers
Drug Manufacturers - Specialty & GenericIndicators:|
Key Statistics
Company
Market Cap5.36B USD
Enterprise Value5.47B USD
Revenue (TTM)288.06M USD
Gross Profit145.08M USD
Net Income (TTM)-68.92M USD
Revenue/Share3.320 USD
Last Price60.02 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees216
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)354.26
P/E (Forward)11.12
PEG—
EV/EBITDA117.38
EV/Revenue19.00
P/S19.13
P/B50.38
EPS (TTM)0.17
EPS (Forward)5.57
52W Range
11.8595% of range62.30
52W High62.30 USD
52W Low11.85 USD
Profitability
Gross Margin91.64%
Oper. Margin46.29%
EBITDA Margin16.19%
Profit Margin-43.53%
ROE-154.03%
ROA-21.02%
Growth
Revenue Growth4158.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.69M USD
CapEx (TTM)6.34M USD
FCF Margin3.33%
FCF Yield0.18%
Net Debt-37.96M USD
Net Debt/EBITDA-0.81
Balance Sheet
Debt/Equity4.42
Current Ratio2.22
Quick Ratio1.98
Book Value/Sh1.230 USD
Cash/Share2.505 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)65.13 USD
Target Range59.00 USD – 70.00 USD
# Analysts8
Ownership
Shares Out.88.93M
Float62.11M
Insiders12.69%
Institutions70.12%
Short Interest
Short Ratio9.4d
Short % Float13.91%
Short % Out.11.19%
Shares Short9.95M
Short (prev mo.)11.86M
Technical
SMA 5041.62 (+44.2%)
SMA 20033.24 (+80.6%)
Beta0.42
S&P 52W Chg28.31%
Avg Vol (30d)1.47M
Avg Vol (10d)2.43M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—